Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo
Sponsor: Novartis Pharmaceuticals
Summary
The main purpose of this multicenter, randomized, double-blind, placebo-controlled Phase 2b study is to investigate the safety and efficacy of GIA632 in participants with NSV and to identify the optimal dose to be promoted into the confirmatory Phase 3 program.
Official title: A Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-ranging Phase IIb Study to Assess the Efficacy and Safety of GIA632 in Adult Participants With Non-segmental Vitiligo Followed by an Extension Period
Key Details
Gender
All
Age Range
18 Years - 99 Years
Study Type
INTERVENTIONAL
Enrollment
210
Start Date
2026-03-09
Completion Date
2030-01-28
Last Updated
2026-07-08
Healthy Volunteers
No
Conditions
Interventions
GIA632
GIA632 will be administered during the 48-week core period.
Placebo
Placebo will be administered during the 48-week core period.
Locations (52)
Cahaba Derm and skin hlth ctr 27
Birmingham, Alabama, United States
First OC Dermatology
Fountain Valley, California, United States
MedDerm Associates
San Diego, California, United States
Clinical Trials Research Institute
Thousand Oaks, California, United States
Encore Medical Research
Hollywood, Florida, United States
Mayo Clinic Jacksonville
Jacksonville, Florida, United States
Miami Derm and Laser Institute
Miami, Florida, United States
Global Clinical Professionals
St. Petersburg, Florida, United States
Dawes Fretzin Clinical Rea Group
Indianapolis, Indiana, United States
Hamzavi Dermatology
Fort Gratiot, Michigan, United States
Revival Research Institute
Troy, Michigan, United States
Skin Specialists PC
Omaha, Nebraska, United States
Las Vegas Dermatology
Las Vegas, Nevada, United States
Equity Medical
The Bronx, New York, United States
Oregon Medical Research Center
Portland, Oregon, United States
International Clinical Research Tennessee LCC
Murfreesboro, Tennessee, United States
Bellaire Dermatology Associates
Bellaire, Texas, United States
Center for Clinical Studies
Houston, Texas, United States
Austin Inst for Clinical Research
Pflugerville, Texas, United States
ACRC Trials
Plano, Texas, United States
Virginia Clinical Research
Norfolk, Virginia, United States
Novartis Investigative Site
Sydney, New South Wales, Australia
Novartis Investigative Site
Waitara, New South Wales, Australia
Novartis Investigative Site
Melbourne, Victoria, Australia
Novartis Investigative Site
Calgary, Alberta, Canada
Novartis Investigative Site
Winnipeg, Manitoba, Canada
Novartis Investigative Site
Mississauga, Ontario, Canada
Novartis Investigative Site
Newmarket, Ontario, Canada
Novartis Investigative Site
Toronto, Ontario, Canada
Novartis Investigative Site
Québec, Quebec, Canada
Novartis Investigative Site
Beijing, China
Novartis Investigative Site
Shanghai, China
Novartis Investigative Site
Brest, France
Novartis Investigative Site
Rouen, France
Novartis Investigative Site
Toulouse, France
Novartis Investigative Site
Munich, Bavaria, Germany
Novartis Investigative Site
Bad Bentheim, Germany
Novartis Investigative Site
Hamburg, Germany
Novartis Investigative Site
Münster, Germany
Novartis Investigative Site
Ahmedabad, Gujarat, India
Novartis Investigative Site
Bangalore, Karnataka, India
Novartis Investigative Site
Belagavi, Karnataka, India
Novartis Investigative Site
Mysore, Karnataka, India
Novartis Investigative Site
Nashik, Maharashtra, India
Novartis Investigative Site
Ancona, AN, Italy
Novartis Investigative Site
Rozzano, MI, Italy
Novartis Investigative Site
Urayasu, Chiba, Japan
Novartis Investigative Site
Kofu, Yamanashi, Japan
Novartis Investigative Site
Niigata, Japan
Novartis Investigative Site
Amsterdam, North Holland, Netherlands
Novartis Investigative Site
Rotterdam, South Holland, Netherlands
Novartis Investigative Site
Barcelona, Spain